NasdaqCM - Delayed Quote USD

Lipocine Inc. (LPCN)

4.7977 +0.2777 (+6.14%)
At close: April 26 at 4:00 PM EDT
4.7983 +0.00 (+0.01%)
After hours: April 26 at 5:46 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
-2,850.8180
-2,850.8180
500.0000
16,140.8380
--
Cost of Revenue
10,175.2510
10,175.2510
8,556.8880
7,665.5590
9,748.4690
Gross Profit
-13,026.0690
-13,026.0690
-8,056.8880
8,475.2790
-9,748.4690
Operating Expense
4,904.8880
4,904.8880
4,062.4870
5,329.7760
8,247.7950
Operating Income
-17,930.9570
-17,930.9570
-12,119.3750
3,145.5030
-17,996.2640
Net Non Operating Interest Income Expense
1,366.9400
1,366.9400
545.4800
-135.5920
-310.9680
Other Income Expense
212.6900
212.6900
815.9400
-3,644.1100
-2,657.3870
Pretax Income
-16,351.3270
-16,351.3270
-10,757.9550
-634.1990
-20,964.6190
Tax Provision
0.7550
0.7550
0.6810
0.2000
0.2000
Net Income Common Stockholders
-16,352.1710
-16,352.1710
-10,758.6360
-634.3990
-20,964.8190
Average Dilution Earnings
-212.6900
-212.6900
-565.9400
--
--
Diluted NI Available to Com Stockholders
-16,564.8610
-16,564.8610
-11,324.5760
-634.3990
-20,964.8190
Basic EPS
-3.10
--
-2.06
-0.17
-6.46
Diluted EPS
-3.14
--
-2.15
-0.17
-6.46
Basic Average Shares
5,269.6710
--
5,231.6810
5,113.8010
3,275.7690
Diluted Average Shares
5,269.6710
--
5,256.1690
5,113.8010
3,275.7690
Total Operating Income as Reported
-17,930.9570
-17,930.9570
-12,119.3750
3,145.5030
-17,996.2640
Total Expenses
15,080.1390
15,080.1390
12,619.3750
12,995.3350
17,996.2640
Net Income from Continuing & Discontinued Operation
-16,352.0820
-16,352.0820
-10,758.6360
-634.3990
-20,964.8190
Normalized Income
-16,520.1071
-16,520.1071
-11,403.2286
2,025.8013
-19,024.9265
Interest Income
1,366.9400
1,366.9400
572.5780
67.7000
75.6500
Interest Expense
--
--
27.0980
203.2920
386.6180
Net Interest Income
1,366.9400
1,366.9400
545.4800
-135.5920
-310.9680
EBIT
-16,351.3270
-16,351.3270
-10,730.8570
-430.9070
-20,578.0010
EBITDA
-16,322.6660
-16,322.6660
-10,721.4040
-430.5270
-20,574.4470
Reconciled Cost of Revenue
10,175.2510
10,175.2510
8,556.8880
7,665.5590
9,748.4690
Reconciled Depreciation
28.6610
28.6610
9.4530
0.3800
3.5540
Net Income from Continuing Operation Net Minority Interest
-16,352.0820
-16,352.0820
-10,758.6360
-634.3990
-20,964.8190
Total Unusual Items Excluding Goodwill
212.6900
212.6900
815.9400
-3,644.1100
-2,657.3870
Total Unusual Items
212.6900
212.6900
815.9400
-3,644.1100
-2,657.3870
Normalized EBITDA
-16,535.3560
-16,535.3560
-11,537.3440
3,213.5830
-17,917.0600
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0003
0.0003
Tax Effect of Unusual Items
44.6649
44.6649
171.3474
-983.9097
-717.4945
12/31/2020 - 10/22/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TCON TRACON Pharmaceuticals, Inc.
1.8100
+1.12%
 
ATHE Alterity Therapeutics Limited
2.5100
+9.61%
 
EYEN Eyenovia, Inc.
0.6282
-11.68%
 
NRXP NRx Pharmaceuticals, Inc.
3.5400
+12.74%
 
ASLN ASLAN Pharmaceuticals Limited
0.4153
-7.30%
 
CNTB Connect Biopharma Holdings Limited
1.3400
-0.74%
 
IKT Inhibikase Therapeutics, Inc.
1.7100
-8.06%
 
BNOX Bionomics Limited
1.0000
+3.49%
 
VNDA Vanda Pharmaceuticals Inc.
4.6200
+3.12%
 
PTN Palatin Technologies, Inc.
1.8200
+5.81%